Published: Apr 19, 2021
GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) -Arcellx Inc. a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical Officer (CMO) where he will have responsibility for clinical, regulatory and medical affairs and Neeraj Teotia has been named Chief Commercial Officer where he will have responsibility for marketing, sales, and health economics and reimbursement.
“We are excited to strengthen our leadership team with the additions of Chris and Neeraj as they bring significant expertise to Arcellx and reflect our values and culture. They will lead two critically important areas advancing our clinical programs to meet all requirements for regulatory approvals and ensuring successful commercialization post approval,” said Rami Elghandour, Chairman and Chief Executive Officer of Arcellx. “Chris will le
Vanderbilt Seeks Volunteers for COVID-19 Clinical Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Vanderbilt Seeks Volunteers for COVID-19 Clinical Trial
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Phase 3 DREAM3R trial opens for malignant pleural mesothelioma
The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study builds on signals of effectiveness found in independent single-arm phase two trials, PrE0505 and DREAM. These trials evaluated durvalumab immunotherapy during and after standard chemotherapy.
DREAM3R will determine if concurrent chemo-immunotherapy can improve outcomes in malignant pleural mesothelioma, especially for the majority of patients with the epithelioid subtype. Both the DREAM and PrE0505 phase 2 trials showed remarkable results in MPM with the combination of chemotherapy and durvalumab, and warrant confirmation in a randomized phase 3 trial.
E-Mail
IMAGE: Patrick Forde, MD, is the lead US investigator for the newly opened DREAM3R clinical trial, which is evaluating chemo-immunotherapy in patients with malignant pleural mesothelioma. view more
Credit: Johns Hopkins University
The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study builds on signals of effectiveness found in independent single-arm phase two trials, PrE0505 and DREAM. These trials evaluated durvalumab immunotherapy during and after standard chemotherapy. DREAM3R will determine if concurrent chemo-immunotherapy can improve outcomes in malignant pleural mesothelioma, especially for the majority of patients with the epithelioid subtype, said lead US investigator Patrick Forde, MD, of Johns Hopkins University. Both the DREAM and PrE0505 phase 2 trials showed remarkable results in MPM with the combi